美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Veraxa Biotech Holding AG

1.51

-0.0100-0.66%

盤後：1.510.0008+0.05%16:15 EDT

成交量：4.75萬

成交額：7.30萬

市值：2.14億

市盈率：7.05

高：1.59

開：1.56

低：1.50

收：1.52

52周最高：27.36

52周最低：1.27

股本：1.41億

流通股本：4,095.75萬

量比：0.30

換手率：0.12%

股息：- -

股息率：- -

每股收益(TTM):0.2142

每股收益(LYR):-5.8037

淨資產收益率：-871.42%

總資產收益率：-49.99%

市淨率：-11.19

市盈率(LYR):-0.26

資料載入中...

總覽公司新聞資訊公告

Veraxa Biotech AG：體外概念驗證研究取得積極成果，有望融合雙方技術與專長開創全新AOC療法

Veraxa Biotech與Secarna Pharmaceuticals達成抗體寡核苷酸偶聯聯盟研究里程碑

Veraxa Biotech Holding AG強化專利佈局，築牢核心技術平台與產品管線護城河

Veraxa Biotech攜手OmniAb，推進創新雙特異性抗體偶聯藥物Vxa-222項目取得新進展

Veraxa Biotech股東大會全票通過所有議案，戰略靈活性獲強化，助力未來增長

Veraxa Biotech任命Christoph Erkel為首席科學官，以推進Bitac®技術平台及產品組合

Veraxa Biotech攜手Ardigen，啓動AI賦能藥物發現合作，助力Bitac®管線擴張

Veraxa Biotech任命Carl Von Halem為臨時首席財務官，接替Torsten Bürgermeister

Veraxa Biotech 發布業務進展，詳述合作戰略與研發時間表

Veraxa Biotech在2026年BIO國際大會上確立新型Bitac-ADC技術平台的體外概念驗證並啓動合作洽談

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/VRXA/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.51,"timestamp":1789588800000,"preClose":1.52,"halted":0,"volume":47548,"hourTrading":{"tag":"盘后","latestPrice":1.5108,"preClose":1.51,"latestTime":"16:15 EDT","volume":53,"amount":80.0629978,"timestamp":1789589725347,"change":0.0008,"changeRate":0.00053,"amplitude":0.00053},"delay":0,"changeRate":-0.006578947368421058,"floatShares":40957496,"shares":141407813,"eps":0.2142,"marketStatus":"盤後交易","change":-0.01,"latestTime":"09-16 16:35:07 EDT","open":1.56,"high":1.59,"low":1.495,"amount":72969,"amplitude":0.0625,"askPrice":1.67,"askSize":200,"bidPrice":1.39,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.52,"preHourTrading":{"tag":"盘前","latestPrice":1.54,"preClose":1.52,"latestTime":"09:08 EDT","volume":4114,"amount":6786.946023,"timestamp":1789564081073,"change":0.02,"changeRate":0.013158,"amplitude":0.105263},"postHourTrading":{"tag":"盘后","latestPrice":1.5108,"preClose":1.51,"latestTime":"16:15 EDT","volume":53,"amount":80.0629978,"timestamp":1789589725347,"change":0.0008,"changeRate":0.00053,"amplitude":0.00053},"volumeRatio":0.298964},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":40957496,"roa":"-49.99%","roe":"-871.42%","lyrEps":-5.803658,"volumeRatio":0.298964,"shares":141407813,"dividePrice":0,"high":1.59,"amplitude":0.0625,"preClose":1.52,"low":1.495,"week52Low":1.27,"pbRate":"-11.19","psRate":"7528.38","week52High":27.36,"institutionHeld":0,"latestPrice":1.51,"committee":-0.333333,"eps":0.2142,"divideRate":0,"volume":47548,"delay":0,"ttmEps":0.2142,"open":1.56,"prevYearClose":18.65,"prevWeekClose":1.65,"prevMonthClose":1.35,"prevQuarterClose":1.88,"fiveDayClose":1.59,"twentyDayClose":1.79,"sixtyDayClose":4.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-09-15","current":7.049486,"percent":0.176471,"low":-3.022108,"twenty":-2.801269,"median":-1.377349,"eighty":-1.094949,"high":-0.413162,"avg":-1.785283,"sd":0.924748,"marketCap":230494735},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725},{"date":"2026-08-28","current":-1.03732,"twenty":-1.349054,"median":-1.281094,"eighty":-1.194963,"marketCap":36312933},{"date":"2026-09-04","current":-2.622384,"twenty":-1.391748,"median":-1.265172,"eighty":-0.552029,"marketCap":216353953},{"date":"2026-09-11","current":-2.842124,"twenty":-2.738773,"median":-1.34261,"eighty":-1.03732,"marketCap":233322891},{"date":"2026-09-15","current":-2.834144,"twenty":-2.801269,"median":-1.377349,"eighty":-1.094949,"marketCap":230494735}],"updateTime":1789590907561},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VRXA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1172247840","title":"Veraxa Biotech AG：體外概念驗證研究取得積極成果，有望融合雙方技術與專長開創全新AOC療法","url":"https://stock-news.laohu8.com/highlight/detail?id=1172247840","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172247840?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:44","pubTimestamp":1787571855,"startTime":"0","endTime":"0","summary":"Veraxa Biotech AG近日宣布，一项成功的体外概念验证研究初步显示出令人振奋的潜力——通过整合双方的尖端技术与深厚专业知识，有望催生新一代抗体偶联物的诞生。由此产生的协同效应，或许正是解锁AOC药物更广阔应用空间的关键钥匙。Veraxa Biotech AG方面对此成果表示高度认可，并认为这是公司发展战略中的一个重要里程碑。借助此次合作所积累的经验和数据，后续的研发管线有望得到显著充实和加速。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156560832","title":"Veraxa Biotech與Secarna Pharmaceuticals達成抗體寡核苷酸偶聯聯盟研究里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1156560832","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156560832?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:42","pubTimestamp":1787571733,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG及其合作伙伴Secarna Pharmaceuticals，在抗体寡核苷酸偶联物联盟框架下，成功跨越了一项关键研究里程碑。通过将抗体的靶向特异性与寡核苷酸的治疗潜力相结合，该联盟正致力于开发新一代精准医疗方案。双方团队对此次合作成果表示高度认可，并强调这一里程碑的达成，凝聚了跨学科研究的智慧与不懈努力。展望未来，Veraxa与Secarna将继续深化协作，加速推进项目向临床前及临床阶段转化，以期为患者带来更具变革性的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178040350","title":"Veraxa Biotech Holding AG強化專利佈局，築牢核心技術平台與產品管線護城河","url":"https://stock-news.laohu8.com/highlight/detail?id=1178040350","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178040350?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 19:01","pubTimestamp":1785322874,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG正全力扩充其专利组合，旨在为公司的核心技术平台与候选产品构建起坚实的知识产权堡垒。这一举措，不仅彰显了企业对创新成果的深度保护，更预示着其在生物科技领域长期战略布局的进一步深化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183111407","title":"Veraxa Biotech攜手OmniAb，推進創新雙特異性抗體偶聯藥物Vxa-222項目取得新進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1183111407","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183111407?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 19:01","pubTimestamp":1785150073,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG正积极推进其新型双特异性抗体药物偶联物（ADC）项目Vxa-222。这一里程碑式的进展，源自其与OmniAb共同开展的发现合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130159461","title":"Veraxa Biotech股東大會全票通過所有議案，戰略靈活性獲強化，助力未來增長","url":"https://stock-news.laohu8.com/highlight/detail?id=1130159461","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130159461?lang=zh_tw&edition=fundamental","pubTime":"2026-07-25 04:06","pubTimestamp":1784923570,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG在临时股东大会上传来捷报——所有提案均获股东一致通过。此举旨在增强公司的战略灵活性，为未来扩张奠定坚实基础。会议审议的各项决议，从资本结构调整到管理层授权，无不彰显出公司对长远布局的深远考量。通过赋予董事会更大的操作空间，Veraxa Biotech将能够更敏捷地应对市场波动，灵活调配资源。随着本次股东大会的圆满落幕，Veraxa Biotech正以更优化的治理结构和更清晰的路径，迎接下一阶段的成长挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169769269","title":"Veraxa Biotech任命Christoph Erkel為首席科學官，以推進Bitac®技術平台及產品組合","url":"https://stock-news.laohu8.com/highlight/detail?id=1169769269","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169769269?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 19:08","pubTimestamp":1784804909,"startTime":"0","endTime":"0","summary":"生物技术公司Veraxa Biotech Holding AG (VRXA) 宣布，任命Christoph Erkel博士为其首席科学官。这一关键人事任命旨在加速其Bitac®技术平台的开发进程，并推动整体产品组合的拓展与深化。Erkel博士在药物研发与技术创新领域拥有丰富的经验，他的加入预计将为公司核心技术的发展注入新的动力，并助力其管线产品向临床应用阶段迈进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119455367","title":"Veraxa Biotech攜手Ardigen，啓動AI賦能藥物發現合作，助力Bitac®管線擴張","url":"https://stock-news.laohu8.com/highlight/detail?id=1119455367","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119455367?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 19:00","pubTimestamp":1783940417,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG宣布，将与Ardigen公司启动一项人工智能赋能的药物发现合作。此次合作旨在支持其不断增长的Bitac®产品管线的发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107741368","title":"Veraxa Biotech任命Carl Von Halem為臨時首席財務官，接替Torsten Bürgermeister","url":"https://stock-news.laohu8.com/highlight/detail?id=1107741368","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107741368?lang=zh_tw&edition=fundamental","pubTime":"2026-07-11 04:06","pubTimestamp":1783713985,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG已任命Carl Von Halem担任临时首席财务官，他将接替即将离任的Torsten Bürgermeister。此项人事变动即刻生效，标志着公司财务管理层进入新的过渡阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152479812","title":"Veraxa Biotech 發布業務進展，詳述合作戰略與研發時間表","url":"https://stock-news.laohu8.com/highlight/detail?id=1152479812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152479812?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 19:03","pubTimestamp":1783335806,"startTime":"0","endTime":"0","summary":"Veraxa Biotech 提供了最新的业务动态，并进一步披露了其合作战略与研发管线的详细时间规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125607903","title":"Veraxa Biotech在2026年BIO國際大會上確立新型Bitac-ADC技術平台的體外概念驗證並啓動合作洽談","url":"https://stock-news.laohu8.com/highlight/detail?id=1125607903","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125607903?lang=zh_tw&edition=fundamental","pubTime":"2026-06-18 19:01","pubTimestamp":1781780476,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG于2026年BIO国际大会上宣布，其新型Bitac-ADC技术平台已成功完成体外概念验证。公司已同步启动针对该创新平台的全球合作伙伴洽谈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}